Guard Therapeutics

Below is a brief summary of the interim report. The interim report is available in its entirety as an attached document and on the company's website.

Link to interim report: Financial reports - Guard Therapeutics

By ”Guard Therapeutics” or ”Company” is meant Guard Therapeutics International AB (publ) with corporate ID no. 556755–3226.

SUMMARY OF INTERIM REPORT
Second quarter, April–June 2025
Net sales: KSEK 0 (0)
Loss for the period: KSEK -32,221 (-23,874)
Earnings per share*: SEK -1.66 (-2.33) 

First six months, January–June 2025
Net sales: KSEK 0 (0)
Loss for the period: KSEK -66,436 (-38,381)
Earnings per share*: SEK -4.19 (-3.78)
              
Equity/asset ratio**: 79% (81)
Cash and cash equivalent: KSEK 100,481 (91,587)

* Earnings per share before and after dilution: Loss of the period divided by the average number of shares during the period.
**Equity/asset ratio: Equity divided by total assets per June 30, 2025.
 
SIGNIFICANT EVENTS IN THE SECOND QUARTER

• On April 4, the outcome of the ongoing rights issue was announced. The issue was subscribed to approximately 70%, and together with an additional around 10% allocated to the underwriters, the company raised approximately SEK 120 million before issue costs.
• On April 11, the company published its annual report for 2024 and simultaneously issued a notice convening the Annual General Meeting, which was held on May 15.
• In May, a positive outcome was announced from the second planned safety review in the ongoing Phase 2b POINTER clinical study, in which the drug candidate RMC-035 is being evaluated as a kidney-protective treatment during open-heart surgery. The independent Data Safety Monitoring Committee (DSMC) recommended that the study continue as planned, as no safety concerns were identified.
• In early June, the company announced that the last patient had been successfully enrolled in the POINTER study.
• During the first week of June, the design of the POINTER study was presented at the annual scientific conference organized by the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) in Vienna, Austria.

SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD
No significant events have been reported after the end of the period.